Manufacturers' views on outcome-based agreements.
Sahar Barjestehvan Waalwijk van Doorn-KhosrovaniLonneke TimmersAnke Pisters-van RoyJoël GijzenNicole M A BlijlevensHaiko J BloemendalPublished in: Journal of market access & health policy (2021)
Market-access interviewees were generally positive about OBAs, however they were more reluctant towards OBAs for registered indications with low response-rate. The definition of performance or outcome and its clinical relevance and validity, the feasibility of OBAs and their administrative burden are relevant aspects that need to be addressed in advance. Ideally, countries should collaborate to share the outline of OBAs and create shared databases to accumulate evidence.
Keyphrases